Eli Lilly & Co. investors have been eagerly awaiting more details on the investigational dual GIP and GLP-1 receptor agonist tirzepatide for type 2 diabetes, but while new Phase II data presented at the American Diabetes Association Scientific Sessions, showed an improvement, it did not alleviate concerns about tolerability.
Lilly announced incremental data from four separate studies of tirzepatide, which showed improvements in markers of beta-cell function and insulin...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?